JP2007023001A - Method for stabilizing thiamine compounds - Google Patents
Method for stabilizing thiamine compounds Download PDFInfo
- Publication number
- JP2007023001A JP2007023001A JP2005211545A JP2005211545A JP2007023001A JP 2007023001 A JP2007023001 A JP 2007023001A JP 2005211545 A JP2005211545 A JP 2005211545A JP 2005211545 A JP2005211545 A JP 2005211545A JP 2007023001 A JP2007023001 A JP 2007023001A
- Authority
- JP
- Japan
- Prior art keywords
- thiamine
- trehalose
- thiamines
- ibuprofen
- stabilizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 15
- 150000003544 thiamines Chemical class 0.000 title claims description 48
- 235000019157 thiamine Nutrition 0.000 claims abstract description 133
- 229960003495 thiamine Drugs 0.000 claims abstract description 91
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims abstract description 89
- 239000011721 thiamine Substances 0.000 claims abstract description 88
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims abstract description 77
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 45
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 45
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 45
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 239000003381 stabilizer Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims description 45
- 229940074410 trehalose Drugs 0.000 claims description 39
- 239000008187 granular material Substances 0.000 claims description 28
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical group [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 claims description 20
- 239000003826 tablet Substances 0.000 claims description 19
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical group O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims description 10
- 229940074409 trehalose dihydrate Drugs 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 claims description 7
- 229960002873 benfotiamine Drugs 0.000 claims description 7
- GFEGEDUIIYDMOX-BMJUYKDLSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(z)-3-[[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-hydroxypent-2-en-3-yl]disulfanyl]-5-hydroxypent-2-en-2-yl]formamide Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(CCO)/SSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N GFEGEDUIIYDMOX-BMJUYKDLSA-N 0.000 claims description 7
- 229960001385 thiamine disulfide Drugs 0.000 claims description 7
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 claims description 6
- 229950006836 fursultiamine Drugs 0.000 claims description 6
- YMEBNAABDXLAJE-GPAWKIAZSA-N [(e)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-3-[[(e)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-butanoyloxypent-2-en-3-yl]disulfanyl]pent-3-enyl] butanoate Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(/CCOC(=O)CCC)SS\C(CCOC(=O)CCC)=C(/C)N(C=O)CC1=CN=C(C)N=C1N YMEBNAABDXLAJE-GPAWKIAZSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000004503 fine granule Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 2
- -1 thiamine compound Chemical class 0.000 abstract description 14
- 238000013329 compounding Methods 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 3
- 239000004615 ingredient Substances 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- 241001411320 Eriogonum inflatum Species 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001106067 Atropa Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940124579 cold medicine Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229940074774 glycyrrhizinate Drugs 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007909 melt granulation Methods 0.000 description 2
- 229960004708 noscapine Drugs 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- AJZJIYUOOJLBAU-CEAXSRTFSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n,n,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 AJZJIYUOOJLBAU-CEAXSRTFSA-N 0.000 description 1
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WHRZCXAVMTUTDD-UHFFFAOYSA-N 1h-furo[2,3-d]pyrimidin-2-one Chemical compound N1C(=O)N=C2OC=CC2=C1 WHRZCXAVMTUTDD-UHFFFAOYSA-N 0.000 description 1
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
- CMCCHHWTTBEZNM-UHFFFAOYSA-N 2-bromo-N-carbamoyl-3-methylbutanamide Chemical compound CC(C)C(Br)C(=O)NC(N)=O CMCCHHWTTBEZNM-UHFFFAOYSA-N 0.000 description 1
- WQOYJMWVNIGIQR-UHFFFAOYSA-N 3-(dithiophen-2-ylmethylidene)-1-methylpiperidine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1N(C)CCCC1=C(C=1SC=CC=1)C1=CC=CS1 WQOYJMWVNIGIQR-UHFFFAOYSA-N 0.000 description 1
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- PUHLHLQBIFRKRD-CSKARUKUSA-N 5-methyl-2-[(E)-2-phenylethenyl]-1,3-benzoxazole Chemical compound N=1C2=CC(C)=CC=C2OC=1\C=C\C1=CC=CC=C1 PUHLHLQBIFRKRD-CSKARUKUSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- BFSMWENDZZIWPW-UHFFFAOYSA-N Isopropamide iodide Chemical compound [I-].C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 BFSMWENDZZIWPW-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000073231 Larrea tridentata Species 0.000 description 1
- 235000006173 Larrea tridentata Nutrition 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- MANKSFVECICGLK-UHFFFAOYSA-K aloxiprin Chemical compound [OH-].[Al+3].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O MANKSFVECICGLK-UHFFFAOYSA-K 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- KSUUMAWCGDNLFK-UHFFFAOYSA-N apronal Chemical compound C=CCC(C(C)C)C(=O)NC(N)=O KSUUMAWCGDNLFK-UHFFFAOYSA-N 0.000 description 1
- 229960004459 apronal Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960002335 bromhexine hydrochloride Drugs 0.000 description 1
- 229960003880 bromisoval Drugs 0.000 description 1
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960002126 creosote Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- HFBYLYCMISIEMM-FFHNEAJVSA-N dihydrocodeine phosphate Chemical compound OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC HFBYLYCMISIEMM-FFHNEAJVSA-N 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 1
- LPRLDRXGWKXRMQ-UHFFFAOYSA-N diphenylpyraline hydrochloride Chemical compound [Cl-].C1C[NH+](C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 LPRLDRXGWKXRMQ-UHFFFAOYSA-N 0.000 description 1
- 229960002392 diphenylpyraline hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 description 1
- 229940061262 ethyl cysteine hydrochloride Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- POOYFSLWYLDQMD-UHFFFAOYSA-N heptacalcium;zinc Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Zn+2] POOYFSLWYLDQMD-UHFFFAOYSA-N 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940077844 iodine / potassium iodide Drugs 0.000 description 1
- 229960001543 isopropamide iodide Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- FGSJNNQVSUVTPW-UHFFFAOYSA-N methoxyphenamine hydrochloride Chemical compound Cl.CNC(C)CC1=CC=CC=C1OC FGSJNNQVSUVTPW-UHFFFAOYSA-N 0.000 description 1
- 229960000659 methoxyphenamine hydrochloride Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002221 methylephedrine Drugs 0.000 description 1
- 229940051020 methylephedrine hydrochloride Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- ZYAINOHNPXGGBU-UHFFFAOYSA-M potassium;3-hydroxy-2-methylbenzoate Chemical compound [K+].CC1=C(O)C=CC=C1C([O-])=O ZYAINOHNPXGGBU-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229950009846 scopolamine butylbromide Drugs 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940048730 senega Drugs 0.000 description 1
- 229950000112 serrapeptase Drugs 0.000 description 1
- 108010038132 serratiopeptidase Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- JWBPVFVNISJVEM-UHFFFAOYSA-M sodium caffeine benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C JWBPVFVNISJVEM-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940068459 sodium pantothenate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- CKHJPWQVLKHBIH-ZDSKVHJSSA-N sulbutiamine Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SS\C(CCOC(=O)C(C)C)=C(\C)N(C=O)CC1=CN=C(C)N=C1N CKHJPWQVLKHBIH-ZDSKVHJSSA-N 0.000 description 1
- 229960003211 sulbutiamine Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229960000896 tipepidine Drugs 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、チアミン類の安定化方法およびチアミン類安定化剤、さらにチアミン類含有製剤およびその製造方法に関する。 The present invention relates to a method for stabilizing thiamines, a thiamine stabilizer, a thiamine-containing preparation and a method for producing the same.
ビタミン類は必須の栄養素であることはよく知られており、その中でも特にビタミンＢ１であるチアミンの欠乏症は、主に末梢神経系、消化器系および心血管系の障害として知られるいわゆる脚気の症状を呈することが知られている。また、チアミンは、特に糖のエネルギー代謝に必要であることが知られており、代謝率が上昇している甲状腺機能亢進症や、妊娠・授乳期のほか、感冒などによる肉体疲労の回復時には、より多くのチアミンの摂取が必要である。チアミンは通常の食品でも摂取できるものの、上記のような状況においては、チアミンおよびチアミン誘導体並びにこれらの塩（以下、チアミン類と称す）を含有する製剤（以下、チアミン類含有製剤と称す）、例えば、顆粒剤、液剤、錠剤などで摂取することができる。また、体力回復のためのドリンク剤やサプリメント、さらには総合感冒薬などで、チアミン類が他の薬効成分と共に配合された医薬品等が既に市販されている。 It is well known that vitamins are essential nutrients, and in particular, deficiency of thiamine, which is vitamin B1, is a so-called beriberi symptom known mainly as a disorder of the peripheral nervous system, digestive system and cardiovascular system. It is known to exhibit. In addition, thiamine is known to be necessary for energy metabolism of sugars in particular. Hyperthyroidism, which has an increased metabolic rate, pregnancy and lactation, and recovery from physical fatigue due to colds, etc. More thiamine intake is needed. Although thiamine can be ingested with ordinary foods, in the above situation, a preparation containing thiamine and a thiamine derivative and salts thereof (hereinafter referred to as thiamines) (hereinafter referred to as thiamine-containing preparation), for example, , Granules, liquids, tablets, etc. In addition, pharmaceuticals and the like in which thiamines are blended with other medicinal ingredients are already on the market, such as drinks and supplements for recovering physical fitness, and general cold medicine.
一方、チアミン類は安定性の確保が難しいことが知られている。一般的にビタミン類の安定性は、ｐＨ、光、熱、水分などの保存環境にも影響されるほか、各種添加剤や異種ビタミンなどの共存成分によっても含量低下を引き起こす。その為、チアミン類をドリンク剤などに配合する場合は、必要配合量よりも多めに配合することもある。
チアミン類の安定化方法については既にいくつか報告されている。例えば、「チアミン類配合液剤」（特許文献１参照）は、アミノ酸の１種であるタウリンを配合すると、チアミン類の液剤中における安定性の向上を図れると記載されている。
また、志望を添加することにより、ビタミンB1類を安定化させる方法を記載した「ビタミンＢ１製剤の安定化方法」（特許文献２参照）や抗酸化剤等を添加する方法なども知られている。
On the other hand, thiamines are known to be difficult to ensure stability. In general, the stability of vitamins is affected not only by the storage environment such as pH, light, heat, and moisture, but also by the coexisting components such as various additives and different types of vitamins. Therefore, when thiamines are blended in a drink or the like, they may be blended in a larger amount than necessary.
Several methods for stabilizing thiamines have already been reported. For example, “thiamine compounded solution” (see Patent Document 1) describes that the stability of thiamines in a solution can be improved by adding taurine, which is one of amino acids.
In addition, a method for stabilizing vitamin B1 by adding an aspiration, a method for stabilizing vitamin B1 preparation (see Patent Document 2), a method for adding an antioxidant, and the like are also known. .
上記の通り、チアミン類の安定化方法に関しては、様々な試みが為されているが、例えば、「チアミン類配合液剤」（特許文献１参照）は、対象製剤が液剤に限られていることと、チアミン類の４２日後の残存率が、７３．０％と充分に高いとはいえないという欠点がある。また、「ビタミンＢ１製剤の安定化方法」（特許文献２参照）は脂肪を製剤に配合するため、高脂血症を合併している患者に投与しにくい。また、抗酸化剤を添加する方法に関しても、安全性の面から好ましくない。 As described above, various attempts have been made to stabilize thiamines. For example, “thiamine compounding liquid” (see Patent Document 1) is that the target preparation is limited to liquids. The remaining ratio of thiamines after 42 days is 73.0%, which is not sufficiently high. In addition, the “stabilization method of vitamin B1 preparation” (see Patent Document 2) is difficult to administer to patients with hyperlipidemia because fat is added to the preparation. Also, the method of adding an antioxidant is not preferable from the viewpoint of safety.
これらの事情から、チアミン類を長期的に安定化させる新しい方法の開発が望まれていた。 Under these circumstances, development of a new method for stabilizing thiamines over the long term has been desired.
本発明は、新しいチアミン類の安定化方法およびチアミン類含有製剤を提供するものである。 The present invention provides a novel method for stabilizing thiamines and a thiamine-containing preparation.
本発明者らは鋭意研究の結果、チアミン類にトレハロースを組み合わせると、チアミン類の安定性が向上することを見出し、トレハロースをチアミン類の安定化に寄与するチアミン類安定化剤として用いることができることを見出した。また、イブプロフェンが、チアミン類の安定性に影響を与えることを見出し、チアミン類にトレハロースを配合すると、イブプロフェンのようなチアミン類の安定性に影響を及ぼす成分を配合しても、チアミン類の安定性が向上することを見出した。 As a result of diligent research, the present inventors have found that when thalamine is combined with trehalose, the stability of thiamine is improved, and trehalose can be used as a thiamine stabilizer that contributes to stabilization of thiamines. I found. In addition, we found that ibuprofen has an effect on the stability of thiamines. When trehalose is added to thiamines, the stability of thiamines can be improved even if ingredients that affect the stability of thiamines such as ibuprofen are added. It was found that the performance is improved.
すなわち本発明は、
１．トレハロースを配合することを特徴とするチアミン類の安定化方法、
２．チアミン類にトレハロースを配合することを特徴とするチアミン類含有製剤の安定化方法、
３．トレハロースを含有することを特徴とするチアミン類安定化剤、
４．トレハロースが、トレハロース２水和物またはトレハロース１／２水和物であることを特徴とする３に記載のチアミン類安定化剤、
５．チアミン類が、チアミン、チアミンジスルフィド、フルスルチアミン、ビスチアミン、ジセチアミン、ビスベンチアミン、ビスイブチアミン、ベンフォチアミンおよびこれらの塩から選ばれる１種以上である３または４に記載のチアミン類安定化剤、
６．チアミン類が、硝酸チアミンである３〜５のいずれか１に記載のチアミン類安定化剤、
７．チアミン類、イブプロフェンおよびトレハロースを含有することを特徴とするチアミン類含有製剤、
８．チアミン類およびトレハロースを含有する造粒物と、イブプロフェンを含有する造粒物を含むチアミン類含有製剤、
９．トレハロースが、トレハロース２水和物またはトレハロース１／２水和物であることを特徴とする７または８に記載のチアミン類含有製剤、
１０．チアミン類が、チアミン、チアミンジスルフィド、フルスルチアミン、ビスチアミン、ジセチアミン、ビスベンチアミン、ビスイブチアミン、ベンフォチアミンおよびこれらの塩から選ばれる１種以上である７〜９のいずれか１に記載のチアミン類含有製剤、
１１．チアミン類が、硝酸チアミンである７〜１０のいずれか１に記載のチアミン類含有製剤、
１２．剤形が錠剤、顆粒剤、細粒剤、散剤またはカプセル剤であることを特徴とする７〜１１のいずれか１に記載のチアミン類含有製剤、
１３．チアミン類、イブプロフェン、およびトレハロースを含有するチアミン類含有製剤において、（Ａ）チアミン類およびトレハロースを含有する混合物、（Ｂ）イブプロフェンを含有する混合物を、各々別に造粒することを特徴とするチアミン類含有製剤の製造方法、
１４．トレハロースが、トレハロース２水和物またはトレハロース１／２水和物であることを特徴とする１３に記載のチアミン類含有製剤の製造方法、
１５．チアミン類が、チアミン、チアミンジスルフィド、フルスルチアミン、ビスチアミン、ジセチアミン、ビスベンチアミン、ビスイブチアミン、ベンフォチアミンおよびこれらの塩から選ばれる１種以上である１３または１４に記載のチアミン類含有製剤の製造方法、
１６．チアミン類が、硝酸チアミンである１３〜１５のいずれか１に記載のチアミン類含有製剤の製造方法、である。
That is, the present invention
1. A method for stabilizing thiamines, characterized by containing trehalose,
2. A method for stabilizing a thiamine-containing preparation, characterized by blending trehalose with thiamines,
3. A thiamine stabilizer characterized by containing trehalose,
4). The thiamine stabilizer according to 3, wherein the trehalose is trehalose dihydrate or trehalose hemihydrate,
5. The thiamine stabilization according to 3 or 4, wherein the thiamine is one or more selected from thiamine, thiamine disulfide, fursultiamine, bisthiamine, dicetiamine, bisbenchamine, bisbutiamine, benfotiamine, and salts thereof. Agent,
6). The thiamine stabilizer according to any one of 3 to 5, wherein the thiamine is thiamine nitrate,
7). A thiamine-containing preparation characterized by containing thiamines, ibuprofen and trehalose;
8). A thiamine-containing preparation comprising a granulated product containing thiamines and trehalose and a granulated product containing ibuprofen;
9. The thiamin-containing preparation according to 7 or 8, wherein the trehalose is trehalose dihydrate or trehalose hemihydrate,
10. The thiamines are any one of 7 to 9, wherein the thiamine is at least one selected from thiamine, thiamine disulfide, fursultiamine, bisthiamine, dicetiamine, bisbenchamine, bisbutiamine, benfotiamine and salts thereof Thiamine-containing preparations,
11. The thiamine-containing preparation according to any one of 7 to 10, wherein the thiamine is thiamine nitrate,
12 The thiamine-containing preparation according to any one of 7 to 11, wherein the dosage form is a tablet, granule, fine granule, powder or capsule,
13. A thiamine-containing preparation containing thiamines, ibuprofen and trehalose, wherein (A) a mixture containing thiamines and trehalose, (B) a mixture containing ibuprofen is granulated separately, A method for producing the preparation containing,
14 The method for producing a thiamine-containing preparation according to 13, wherein the trehalose is trehalose dihydrate or trehalose hemihydrate,
15. The thiamine-containing preparation according to 13 or 14, wherein the thiamine is at least one selected from thiamine, thiamine disulfide, fursultiamine, bisthiamine, discetiamine, bisbenchamine, bisbutiamine, benfotiamine and salts thereof. Manufacturing method,
16. The method for producing a thiamine-containing preparation according to any one of 13 to 15, wherein the thiamine is thiamine nitrate.
本発明により、新しいチアミン類の安定化方法を提供することができ、この方法を利用してチアミン類含有製剤を製造し、長期安定性の優れたチアミン類含有製剤を提供することができる。 According to the present invention, a new method for stabilizing thiamines can be provided, and a thiamine-containing preparation can be produced using this method, and a thiamine-containing preparation having excellent long-term stability can be provided.
本発明にかかるチアミン類は、チアミン、チアミンジスルフィド、フルスルチアミン、ビスチアミン、ジセチアミン、ビスベンチアミン、ビスイブチアミン、ベンフォチアミンおよびこれらの塩などが挙げられるが、特にこれらに限定されない。上記チアミン類の塩としては、硝酸塩、塩酸塩、硫酸塩、リン酸塩などが挙げられる。本発明においては、硝酸チアミンが最も好ましい。これらのチアミン類は公知の化合物であり、市販のものを用いても良く、また公知の方法を用いて製造することも可能である。 Examples of the thiamine according to the present invention include, but are not limited to, thiamine, thiamine disulfide, fullsultiamine, bisthiamine, dicetiamine, bisbenchamine, bisibutiamine, benfotiamine, and salts thereof. Examples of the thiamine salts include nitrates, hydrochlorides, sulfates and phosphates. In the present invention, thiamine nitrate is most preferred. These thiamines are known compounds, which may be commercially available, or can be produced using known methods.
本発明は、上記チアミン類を安定化させるために、トレハロースを配合することを特徴とする。このトレハロースは特に限定されないが、トレハロース１／２水和物、トレハロース２水和物が好ましい。これらトレハロースは公知の化合物であり、市販のものを用いても良く、公知の方法を用いて製造することも可能である。 The present invention is characterized by blending trehalose in order to stabilize the thiamines. The trehalose is not particularly limited, but trehalose hemihydrate and trehalose dihydrate are preferable. These trehalose is a known compound, and a commercially available one may be used, or it can be produced using a known method.
本発明のチアミン類含有製剤は、上記のチアミン類およびトレハロースを含有されていれば良く、また、当該チアミン類含有製剤に含有されるチアミン類の量にも、特に制限はない。また、本発明のチアミン類含有製剤の投与量は、患者の病状に応じて適宜調節が可能であるが、例えば経口剤の場合、チアミン類の１日あたりの投与量として、通常０．１〜５００ｍｇであり、１〜５０ｍｇが好ましく、１〜２５ｍｇがより好ましい。
なお、チアミン類を安定化させるために必要なトレハロースの配合量は、チアミン類１重量部に対して、トレハロースを０．０１〜１００重量部、好ましくは０．１〜５０重量部である。
The thiamine-containing preparation of the present invention only needs to contain the above-mentioned thiamines and trehalose, and the amount of thiamines contained in the thiamine-containing preparation is not particularly limited. The dosage of the thiamine-containing preparation of the present invention can be appropriately adjusted according to the patient's medical condition. For example, in the case of an oral preparation, the daily dosage of thiamine is usually 0.1 to 500 mg, preferably 1 to 50 mg, more preferably 1 to 25 mg.
In addition, the compounding quantity of the trehalose required in order to stabilize thiamines is 0.01-100 weight part with respect to 1 weight part of thiamines, Preferably it is 0.1-50 weight part.
本発明のチアミン類含有製剤は、チアミン類以外の薬効成分を配合することができる。具体的には、アスピリン、アスピリンアルミニウム、サザピリン、エテンザミド、サリチルアミド、イブプロフェン、アセトアミノフェン、イソプロピルアンチピリン等の解熱鎮痛剤、カフェイン、無水カフェイン、安息香酸ナトリウムカフェイン等の中枢神経興奮薬、ブロムワレリル尿素、アリルイソプロピルアセチル尿素等の鎮静剤、マレイン酸クロルフェニラミン、ジフェンヒドラミン、サリチル酸ジフェンヒドラミン、マレイン酸カルビノキサミン、メキタジン、酒石酸アリメマジン、塩酸ジフェニルピラリン、塩酸トリプロリジン、フマル酸クレマスチン等の抗ヒスタミン薬、塩化リゾチーム、ブロメライン、セラペプターゼ、セミアルカリプロティナーゼ、グリチルリチン酸、グリチルリチン酸ジカリウム、グリチルリチン酸アンモニウム、グリチルレチン酸、アズレンスルホン酸ナトリウム等の抗炎症薬、トラネキサム酸等の抗プラスミン剤、リン酸ジヒドロコデイン、リン酸コデイン、塩酸ノスカピン、ノスカピン、臭化水素酸デキストロメトルファン、デキストロメトルファンフェノールフタリン塩、リン酸ジメモルファン、ヒベンズ酸チペピジン、クエン酸チペピジン、塩酸エプラジノン、メチルエフェドリン、塩酸メチルエフェドリン、塩酸メトキシフェナミン、塩酸トリメトキノール、塩酸フェニルプロパノールアミン等の鎮咳薬、塩酸Ｌ−エチルシステイン、グアヤコールスルホン酸カリウム、クレゾール酸カリウム、グアイフェネシン、塩酸ブロムヘキシン、カルボシステイン、塩酸アンブロキソール等の去痰薬、テオフィリン、アミノフィリン、ジプロフィリン等の気管拡張薬、ベラドンナ（総）アルカロイド、べラドンナエキス、ヨウ化イソプロパミド、臭化水素酸スコポラミン、ロートエキス、臭化ブチルスコポラミン、臭化メチルベナクチジウム、ピレンゼピン等の抗アセチルコリン薬、セチルピリジニウム、塩化セチルピリジニウム、ポビドンヨード、グルコン酸クロルヘキシジン、塩化ベンザルコニウム、塩化デカリニウム、チモール、ヨウ素・ヨウ化カリウム、フェノール、塩酸クロルヘキシジン、クレオソート、塩化ベンゼトニウム等の酸化消毒剤、塩酸ジブカイン、アミノ安息香酸エチル、リドカイン、塩酸リドカイン、オキセサゼイン等の局所麻酔剤、ビタミンＡ、ビタミンＢ２、ビタミンＢ６、ビタミンＢ１２、ビタミンＣ、アスコルビン酸カルシウム、ビタミンＤ、ビタミンＥ、コハク酸トコフェノールカルシウムなどのビタミン剤、パントテン酸、パンテノール、パントテン酸カルシウム、パントテン酸ナトリウム、パンテチン、ニコチン酸、ニコチン酸アミド、グルクロン酸、グルクロノラクトン、アミノエチルスルホン酸、ビオチン、γ−オリザノール等の代謝性成分、地竜、ケイヒ、ゴオウ、ショウキョウ、キキョウ、マオウ、カンゾウ、キョウニン、ハンゲ、シャゼンソウ、セネガ、サイコ、ブクリョウ、シンイ等の生薬およびこれら生薬の抽出物（エキス、チンキ等）等を挙げることができるが、これらに限定されるべきものではない。これらの薬効成分は、単一成分を配合しても良く、２種以上のものを組み合わせて配合しても良い。
本発明により製造されるチアミン類含有製剤の剤形は、固形製剤、特に錠剤、顆粒剤、細粒剤、散剤またはカプセル剤であることが好ましく、特に錠剤または顆粒剤が好ましい。
The thiamine-containing preparation of the present invention can contain medicinal ingredients other than thiamines. Specifically, antipyretic analgesics such as aspirin, aspirin aluminum, sazapyrine, ethenamide, salicylamide, ibuprofen, acetaminophen, isopropylantipyrine, central nervous stimulants such as caffeine, anhydrous caffeine, sodium benzoate caffeine, Sedatives such as bromovaleryl urea and allyl isopropyl acetyl urea, chlorpheniramine maleate, diphenhydramine, diphenhydramine salicylate, carbinoxamine maleate, mequitazine, alimemazine tartrate, diphenylpyraline hydrochloride, triprolidine hydrochloride, clemastine fumarate and other antihistamine drugs Lysozyme, bromelain, serrapeptase, semi-alkaline proteinase, glycyrrhizinate, dipotassium glycyrrhizinate, glycyrrhizinate Anti-inflammatory drugs such as monium, glycyrrhetinic acid, sodium azulene sulfonate, antiplasmin drugs such as tranexamic acid, dihydrocodeine phosphate, codeine phosphate, noscapine hydrochloride, noscapine, dextromethorphan hydrobromide, dextromethorphan phenolphthalein Antitussives such as salts, dimemorphan phosphate, tipepidine hibenzate, tipepidine citrate, epradinone hydrochloride, methylephedrine, methylephedrine hydrochloride, methoxyphenamine hydrochloride, trimethquinol hydrochloride, phenylpropanolamine hydrochloride, L-ethylcysteine hydrochloride, guaiacol Expectorants such as potassium sulfonate, potassium cresolate, guaifenesin, bromhexine hydrochloride, carbocysteine, ambroxol hydrochloride, theophylline, aminophylline, di Tracheodilators such as lofilin, belladonna (total) alkaloids, belladonna extract, isopropamide iodide, scopolamine hydrobromide, funnel extract, butylscopolamine bromide, methylbenactidium bromide, pirenzepine and other antiacetylcholine drugs, cetyl Oxidizing disinfectants such as pyridinium, cetylpyridinium chloride, povidone iodine, chlorhexidine gluconate, benzalkonium chloride, decalinium chloride, thymol, iodine / potassium iodide, phenol, chlorhexidine hydrochloride, creosote, benzethonium chloride, dibucaine hydrochloride, aminobenzoic acid Local anesthetics such as ethyl, lidocaine, lidocaine hydrochloride, oxesecasein, vitamin A, vitamin B2, vitamin B6, vitamin B12, vitamin C, calcium ascorbate, vitamin D, Vitamin E, vitamins such as tocophenol calcium succinate, pantothenic acid, panthenol, calcium pantothenate, sodium pantothenate, panthetin, nicotinic acid, nicotinamide, glucuronic acid, glucuronolactone, aminoethylsulfonic acid, biotin, Metabolic components such as γ-oryzanol, crude drugs such as earth dragons, keihi, gooh, gyoza, kyoukyo, maou, licorice, kyounin, hange, shazenso, senega, psycho, bukkyou, shinnyi and extracts of these herbs (extracts, Tincture etc.) can be mentioned, but should not be limited to these. These medicinal components may be blended with a single component or in combination of two or more.
The dosage form of the thiamine-containing preparation produced according to the present invention is preferably a solid preparation, particularly a tablet, granule, fine granule, powder or capsule, and particularly preferably a tablet or granule.
さらに、本発明の効果に影響を及ぼさない範囲内で、製剤中に適当な添加物を加えることができる。具体的には、賦形剤、結合剤、崩壊剤、滑沢剤などを挙げることができる。
賦形剤としては、例えば、結晶セルロース、粉末セルロース、トウモロコシデンプン、バレイショデンプン、軽質無水ケイ酸、含水二酸化ケイ素、二酸化ケイ素、沈降炭酸カルシウム、無水リン酸水素カルシウム、酸化マグネシウム、乳酸カルシウム、ケイ酸カルシウム、メタケイ酸アルミン酸マグネシウム、合成ヒドロタルサイト、合成ケイ酸アルミニウム、乳糖、白糖、Ｄ−マンニトール、エリスリトール、ブドウ糖、果糖などを挙げることができる。
Furthermore, an appropriate additive can be added to the preparation within a range not affecting the effects of the present invention. Specific examples include excipients, binders, disintegrants, and lubricants.
Examples of the excipient include crystalline cellulose, powdered cellulose, corn starch, potato starch, light anhydrous silicic acid, hydrous silicon dioxide, silicon dioxide, precipitated calcium carbonate, anhydrous calcium hydrogen phosphate, magnesium oxide, calcium lactate and silicic acid. Examples include calcium, magnesium aluminate metasilicate, synthetic hydrotalcite, synthetic aluminum silicate, lactose, sucrose, D-mannitol, erythritol, glucose, fructose and the like.
崩壊剤としては、例えば、カルメロース、カルメロースカルシウム、クロスカルメロースナトリウム、低置換度ヒドロキシプロピルセルロース、クロスポビドン、アルギン酸、部分アルファー化デンプン、ベントナイト等を挙げることができる。
結合剤としては、例えば、メチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルアルコール、ポビドン、マクロゴール、アラビアゴム、アルギン酸ナトリウム、カルボキシビニルポリマー、ゼラチン、デキストリン、ペクチン、ポリアクリル酸ナトリウム、プルラン等を挙げることができる。
Examples of the disintegrant include carmellose, carmellose calcium, croscarmellose sodium, low-substituted hydroxypropylcellulose, crospovidone, alginic acid, partially pregelatinized starch, and bentonite.
Examples of the binder include methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, povidone, macrogol, gum arabic, sodium alginate, carboxyvinyl polymer, gelatin, dextrin, pectin, sodium polyacrylate, pullulan and the like. be able to.
滑沢剤としては、例えば、ステアリン酸マグネシウム、ステアリン酸カルシウム、タルク、ショ糖脂肪酸エステル、グリセリン脂肪酸エステル、ポリエチレングリコール、ラウリル硫酸ナトリウム、硬化油等を挙げることができる。 Examples of the lubricant include magnesium stearate, calcium stearate, talc, sucrose fatty acid ester, glycerin fatty acid ester, polyethylene glycol, sodium lauryl sulfate, and hardened oil.
これらの添加物は、１種または２種以上を組み合わせても良い。 These additives may be used alone or in combination of two or more.
本発明のチアミン類含有製剤は、上記成分を公知の製造方法にて製剤化することにより得ることができる。例えば、粉砕、混合、造粒、圧縮、乾燥などを必要に応じて行なうことができる。造粒の方法としては、例えば湿式造粒法、乾式造粒法、溶融造粒法などを挙げることができる。得られた造粒物は、必要に応じて圧縮処理を行ない、成型することができる。圧縮処理は一般的な成型機を用いて、所望の圧縮成型圧にて行なうことができる。 The thiamine-containing preparation of the present invention can be obtained by formulating the above components by a known production method. For example, pulverization, mixing, granulation, compression, drying and the like can be performed as necessary. Examples of the granulation method include a wet granulation method, a dry granulation method, and a melt granulation method. The obtained granulated product can be molded by performing a compression treatment as necessary. The compression process can be performed using a general molding machine at a desired compression molding pressure.
チアミン類またはトレハロースの安定性に影響を及ぼすような成分を、本発明の製剤に含有させる場合には、その製造工程において、チアミン類およびトレハロースを含有する混合物を造粒し、別にチアミン類またはトレハロースの安定性に影響を及ぼす成分を含有する混合物を造粒することが望ましい。チアミン類の安定性に影響を及ぼす成分の例として、イブプロフェンを挙げることができる。本発明のチアミン類含有製剤にイブプロフェンを含有させる際には、（Ａ）チアミン類とトレハロースを含有する混合物、（Ｂ）イブプロフェンを含有する混合物を、各々別に造粒し、（Ａ）を含有する造粒物と、（Ｂ）を含有する造粒物を含有する混合物を必要に応じて圧縮し、本発明の製剤を得ることができる。 When a component that affects the stability of thiamines or trehalose is contained in the preparation of the present invention, a mixture containing thiamines and trehalose is granulated in the production process, and thiamines or trehalose is separately prepared. It is desirable to granulate a mixture containing components that affect the stability of the. An example of a component that affects the stability of thiamines is ibuprofen. When containing ibuprofen in the thiamines-containing preparation of the present invention, (A) a mixture containing thiamines and trehalose and (B) a mixture containing ibuprofen are granulated separately, and contain (A). The granule and the mixture containing the granule containing (B) may be compressed as necessary to obtain the preparation of the present invention.
以下に実施例を示して本発明を説明するが、本発明はこれのみに限定されるべきものではない。 Hereinafter, the present invention will be described with reference to examples. However, the present invention should not be limited to these examples.
（実施例１）
表１に記載されている成分を混合攪拌造粒後、解砕、乾燥後、さらに整粒して、Ａ顆粒を得た。
Example 1
The ingredients listed in Table 1 were mixed and stirred, granulated, crushed, dried, and further sized to obtain A granules.
表１
表２に記載されている成分を、混合、溶融造粒後に冷却し、さらに整粒してＢ顆粒を得た。 The components described in Table 2 were mixed and cooled after melt granulation, and further sized to obtain B granules.
表２
表３に記載されている成分を混合、攪拌造粒後に解砕、乾燥し、さらに整粒してＣ顆粒を得た。 The ingredients listed in Table 3 were mixed, stirred and granulated, then crushed and dried, and further sized to obtain C granules.
表３
上記の工程により得られたＡ顆粒、Ｂ顆粒、Ｃ顆粒を混合、整粒し、表４に示した成分をあわせて、混合、次いで圧縮を行い、チアミン類含有錠剤を得た。 A granule, B granule, and C granule obtained by the above steps were mixed and sized, and the components shown in Table 4 were mixed, mixed, and then compressed to obtain a thiamine-containing tablet.
表４
得られた錠剤をビン密栓にて５０℃で保存し、保存開始から３０日後の硝酸チアミンの残存率を測定した。結果を表ａに示す。 The obtained tablets were stored in a bottle cap at 50 ° C., and the residual rate of thiamine nitrate was measured 30 days after the start of storage. The results are shown in Table a.
（比較例１）
実施例１のＡ顆粒の成分中のトレハロース２水和物をエリスリトールに換えて、実施例１と同様の操作を行い、得られた錠剤をビン密栓にて５０℃で保存し、保存開始から３０日後の硝酸チアミンの残存率を測定した。結果を表ａに示す。
(Comparative Example 1)
The trehalose dihydrate in the ingredients of the granule A in Example 1 was changed to erythritol, and the same operation as in Example 1 was performed. The obtained tablets were stored at 50 ° C. in a bottle stopper, and 30 The residual ratio of thiamine nitrate after the day was measured. The results are shown in Table a.
（比較例２）
下記の表５の成分から、実施例１に記載した方法と同様に各々Ｄ顆粒、Ｅ顆粒、Ｆ顆粒を製造した。
(Comparative Example 2)
D granules, E granules, and F granules were produced from the components shown in Table 5 in the same manner as in the method described in Example 1.
表５
これらのＤ顆粒、Ｅ顆粒、Ｆ顆粒に下記の表６の成分を加え、実施例１と同様の方法にてチアミン類含有錠剤の素錠を得た。 The components shown in Table 6 below were added to these D granules, E granules, and F granules, and uncoated tablets of thiamine-containing tablets were obtained in the same manner as in Example 1.
表６
さらに、表７の成分を用いて、得られた素錠をフィルムコーティングし、チアミン類含有錠剤を得た。 Furthermore, the obtained uncoated tablet was film-coated using the components in Table 7 to obtain thiamine-containing tablets.
表７
得られた錠剤をビン密栓にて５０℃で保存し、保存開始から３０日後の硝酸チアミンの残存率を測定した。結果を表ａに示す。 The obtained tablets were stored in a bottle stopper at 50 ° C., and the residual rate of thiamine nitrate was measured 30 days after the start of storage. The results are shown in Table a.
表ａ
表ａの結果より、硝酸チアミンと同一の顆粒に配合する賦形剤をＤ−マンニトール、エリスリトール、トレハロース２水和物にて比較したところ、トレハロース２水和物が、硝酸チアミンを安定化させることを見出した。 From the results in Table a, when excipients blended in the same granules as thiamine nitrate were compared with D-mannitol, erythritol, and trehalose dihydrate, trehalose dihydrate stabilized thiamine nitrate. I found.
（試験例１）
下記の表８の成分から、実施例１に記載した方法と同様に各々Ｇ顆粒、Ｈ顆粒、Ｉ顆粒を製造した。
(Test Example 1)
From the components shown in Table 8 below, G granules, H granules and I granules were produced in the same manner as in the method described in Example 1.
表８
これらのＧ顆粒、Ｈ顆粒、Ｉ顆粒に下記の表９の成分を加え、実施例１と同様の方法にてチアミン類含有錠剤の素錠を得た。 The components shown in Table 9 below were added to these G granules, H granules, and I granules, and uncoated tablets of thiamine-containing tablets were obtained in the same manner as in Example 1.
表９
さらに、表１０の成分を用いて、得られた素錠をフィルムコーティングし、チアミン類含有錠剤を得た。 Furthermore, the obtained uncoated tablets were film-coated using the components shown in Table 10 to obtain thiamine-containing tablets.
表１０
得られた錠剤をビン密栓にて４０℃または５０℃で保存し、保存開始から３０日後の硝酸チアミンの残存率を測定した。結果を表ｂに示す。 The obtained tablets were stored in a bottle stopper at 40 ° C. or 50 ° C., and the residual ratio of thiamine nitrate was measured 30 days after the start of storage. The results are shown in Table b.
表ｂ
硝酸チアミンに他の薬効成分を組み合わせ、賦形剤としてＤ―マンニトールを添加して造粒処理、次いで圧縮処理を行い、得られた錠剤を瓶に密閉し、長期安定性を検討した。４０℃で３０日間の密閉保存では、硝酸チアミンの残存率に影響は無かったものの、高温度下の５０℃で３０日間密閉保存を行なった場合、硝酸チアミンの残存率は７１．５％と、硝酸チアミンの含量低下が認められた（試験例１）。 Other medicinal ingredients were combined with thiamine nitrate, D-mannitol was added as an excipient, granulated, and then compressed, and the resulting tablets were sealed in a bottle to examine long-term stability. In the sealed storage at 40 ° C. for 30 days, the residual rate of thiamine nitrate was not affected, but when the sealed storage was performed at 50 ° C. for 30 days under high temperature, the residual rate of thiamine nitrate was 71.5%. A decrease in thiamine nitrate content was observed (Test Example 1).
（参考例１）
硝酸チアミン０．５ｇに、表１１に記載の各成分を加え、さらに結晶セルロースを加えて４５．０ｇにしたものを７０℃で５日間保存し、硝酸チアミンと各成分の配合変化試験を行なった。
(Reference Example 1)
Each component listed in Table 11 was added to 0.5 g of thiamine nitrate, and further 45.0 g of crystalline cellulose was added and stored at 70 ° C. for 5 days, and a blending change test of thiamine nitrate and each component was performed. .
表１１
結果を表ｃに示す。 The results are shown in Table c.
表ｃ
表ｃから、イブプロフェンが硝酸チアミンの含量低下の起因物質であることが認められた。 From Table c, it was confirmed that ibuprofen was a causative substance for the decrease in thiamine nitrate content.
本発明により、新しい地アミン類を安定化させる方法を提供することができ、本発明を利用して、チアミン類を含有する製剤、例えば、風邪薬や肉体疲労回復のための栄養補給剤などを提供することができる。
According to the present invention, it is possible to provide a method for stabilizing new ground amines. By using the present invention, a preparation containing thiamines such as a cold medicine and a nutritional supplement for recovery from physical fatigue can be provided. Can be provided.
Claims (16)
The method for producing a thiamine-containing preparation according to any one of claims 13 to 15, wherein the thiamine is thiamine nitrate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005211545A JP4864369B2 (en) | 2005-07-21 | 2005-07-21 | Method for stabilizing thiamines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005211545A JP4864369B2 (en) | 2005-07-21 | 2005-07-21 | Method for stabilizing thiamines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007023001A true JP2007023001A (en) | 2007-02-01 |
| JP4864369B2 JP4864369B2 (en) | 2012-02-01 |
Family
ID=37784242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005211545A Active JP4864369B2 (en) | 2005-07-21 | 2005-07-21 | Method for stabilizing thiamines |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4864369B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011063580A (en) * | 2009-06-30 | 2011-03-31 | Kowa Co | Composition |
| CN103804368A (en) * | 2012-11-07 | 2014-05-21 | 江苏兄弟维生素有限公司 | Recovery method of thiamine nitrate in thiamine nitrate mother liquor |
| JPWO2012147986A1 (en) * | 2011-04-28 | 2014-07-28 | 興和株式会社 | Stable pharmaceutical composition |
| JP2019502658A (en) * | 2015-12-10 | 2019-01-31 | ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． | Vitamin preparation |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09268127A (en) * | 1996-04-01 | 1997-10-14 | Taisho Pharmaceut Co Ltd | Solid preparation composition containing vitamin b1 derivative |
| JPH10338633A (en) * | 1997-04-08 | 1998-12-22 | Takeda Chem Ind Ltd | Composition for treatment and prevention for periodontal disease |
| JP2000159789A (en) * | 1992-12-02 | 2000-06-13 | Hayashibara Biochem Lab Inc | Production of powder composition and powder composition |
| JP2002097141A (en) * | 2000-09-19 | 2002-04-02 | Nikken Chem Co Ltd | Aqueous solution of vitamin b |
| JP2004002482A (en) * | 2003-09-09 | 2004-01-08 | Rohto Pharmaceut Co Ltd | Pharmaceutical preparation containing aminosugar |
| JP2005120058A (en) * | 2003-10-20 | 2005-05-12 | Ss Pharmaceut Co Ltd | Ibuprofen-containing tablet and method for producing the same |
-
2005
- 2005-07-21 JP JP2005211545A patent/JP4864369B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000159789A (en) * | 1992-12-02 | 2000-06-13 | Hayashibara Biochem Lab Inc | Production of powder composition and powder composition |
| JPH09268127A (en) * | 1996-04-01 | 1997-10-14 | Taisho Pharmaceut Co Ltd | Solid preparation composition containing vitamin b1 derivative |
| JPH10338633A (en) * | 1997-04-08 | 1998-12-22 | Takeda Chem Ind Ltd | Composition for treatment and prevention for periodontal disease |
| JP2002097141A (en) * | 2000-09-19 | 2002-04-02 | Nikken Chem Co Ltd | Aqueous solution of vitamin b |
| JP2004002482A (en) * | 2003-09-09 | 2004-01-08 | Rohto Pharmaceut Co Ltd | Pharmaceutical preparation containing aminosugar |
| JP2005120058A (en) * | 2003-10-20 | 2005-05-12 | Ss Pharmaceut Co Ltd | Ibuprofen-containing tablet and method for producing the same |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011063580A (en) * | 2009-06-30 | 2011-03-31 | Kowa Co | Composition |
| JPWO2012147986A1 (en) * | 2011-04-28 | 2014-07-28 | 興和株式会社 | Stable pharmaceutical composition |
| JP2017105815A (en) * | 2011-04-28 | 2017-06-15 | 興和株式会社 | Stable pharmaceutical composition |
| JP2019019132A (en) * | 2011-04-28 | 2019-02-07 | 興和株式会社 | Stable pharmaceutical composition |
| CN103804368A (en) * | 2012-11-07 | 2014-05-21 | 江苏兄弟维生素有限公司 | Recovery method of thiamine nitrate in thiamine nitrate mother liquor |
| JP2019502658A (en) * | 2015-12-10 | 2019-01-31 | ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． | Vitamin preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4864369B2 (en) | 2012-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5809736B2 (en) | New pharmaceutical composition containing loxoprofen | |
| JP5465824B2 (en) | Pharmaceutical preparation and method for producing the same | |
| JP2019019132A (en) | Stable pharmaceutical composition | |
| JP2021073307A (en) | Antipyretic analgesic composition | |
| JP5134802B2 (en) | Method for preventing reduction of bromhexine hydrochloride content | |
| JP4864369B2 (en) | Method for stabilizing thiamines | |
| JP6009967B2 (en) | Solid preparation | |
| JP5571237B2 (en) | Loxoprofen-containing pharmaceutical composition | |
| JP2013163698A (en) | Pharmaceutical preparation and method for producing the same | |
| JP6114573B2 (en) | Solid formulation containing loxoprofen sodium and antacid | |
| JP2017066133A (en) | Ibuprofen-containing solid preparation with high stability and quick-acting properties | |
| JP6260736B1 (en) | Solid preparation | |
| RU2007147953A (en) | PHARMACEUTICAL RECIPES OF MICRONIZED (4-CHLOROPHENYL) [4- (4-pyridylmethyl) -phthalazin-1-yl] AND ITS SALTS WITH IMMEDIATE EXCESSION AND HIGH CONTENT | |
| KR20210052495A (en) | Pharmaceutical composition for oral administration | |
| JP4899304B2 (en) | Solid preparation for internal use containing ambroxol hydrochloride | |
| JP2018076312A (en) | Pharmaceutical composition containing acetaminophen, isopropylantipyrine and ginger-derived components | |
| JP2017002038A (en) | Solid preparations | |
| JP2004331660A (en) | Pharmaceutical composition | |
| JP2004339211A (en) | Pharmaceutical composition | |
| JP5433053B2 (en) | Loxoprofen-containing pharmaceutical composition | |
| JP6113978B2 (en) | Antipyretic analgesic pharmaceutical composition | |
| JP2019137651A (en) | Pharmaceutical composition | |
| JP2003300874A (en) | Solid preparation containing pseudoephedrine hydrochloride | |
| JP2012246260A (en) | Granular material | |
| JP2013221022A (en) | Ephedrine (salt)-containing particle and solid preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080206 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080206 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110706 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110706 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110804 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110928 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111102 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111109 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141118 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4864369 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141118 Year of fee payment: 3 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141118 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |